Roth Capital Positive on Cytokinetics (CYTK) Following 'Milestone' ALS Study Enrollment
Tweet Send to a Friend
Roth Capital affirms Cytokinetics (Nasdaq: CYTK) at Buy with a price target of $22 after the announced the completion of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
